Package 'SurrogateTest'

October 12, 2022

Type Package
Title Early Testing for a Treatment Effect using Surrogate Marker Information
Version 1.3
Date 2021-11-15
Author Layla Parast
Maintainer Layla Parast <pre></pre>
Description Provides functions to test for a treatment effect in terms of the difference in survival between a treatment group and a control group using surrogate marker information obtained at some early time point in a time-to-event outcome setting. Nonparametric kernel estimation is used to estimate the test statistic and perturbation resampling is used for variance estimation. More details will be available in the future in: Parast L, Cai T, Tian L (2019) "Using a Surrogate Marker for Early Testing of a Treatment Effect" Biometrics, 75(4):1253-1263. <doi:10.1111 biom.13067="">.</doi:10.1111>
License GPL
Imports stats, survival
NeedsCompilation no
Repository CRAN
Date/Publication 2021-11-16 08:00:05 UTC
R topics documented:
dataA 2 dataB 3 delta.estimate 4 design.study 5 early.delta.test 8 recover.B 11
Index 14

2 dataA

dataA

Hypothetical Study A data

Description

Hypothetical Study A data to be used in examples; t=1 and the landmark time = 0.50.

Usage

data(dataA)

Format

A list with 6 elements representing 1000 observations from a control group and 1000 observations from a treatment group:

- s1 Surrogate marker measurement for treated observations; this marker is measured at time = 0.5. For observations that experience the primary outcome or are censored before 0.5, this value is NA
- x1 The observed event or censoring time for treated observations; X = min(T, C) where T is the time of the primary outcome and C is the censoring time.
- delta1 The indicator identifying whether the treated observation was observed to have the event or was censored; D =1*(T<C) where T is the time of the primary outcome and C is the censoring time.
- so Surrogate marker measurement for control observations; this marker is measured at time = 0.5. For observations that experience the primary outcome or are censored before 0.5, this value is NA.
- x0 The observed event or censoring time for control observations; X = min(T, C) where T is the time of the primary outcome and C is the censoring time.
- delta0 The indicator identifying whether the control observation was observed to have the event or was censored; D = 1*(T < C) where T is the time of the primary outcome and C is the censoring time.

Details

Note that if the observation is censored or experienced the primary outcome before the landmark time of 0.50, the surrogate marker measurement is not observed and coded NA.

Examples

```
data(dataA)
names(dataA)
```

dataB 3

dataB

Hypothetical Study B data

Description

Hypothetical Study B data to be used in examples; landmark time = 0.50.

Usage

data(dataB)

Format

A list with 6 elements representing 800 observations from a control group and 800 observations from a treatment group:

- s1 Surrogate marker measurement for treated observations; this marker is measured at time = 0.5. For observations that experience the primary outcome or are censored before 0.5, this value is NA.
- x1 The observed event or censoring time for treated observations; X = min(T, C) where T is the time of the primary outcome and C is the censoring time. This time is administratively censored at 0.55 (see details).
- delta1 The indicator identifying whether the treated observation was observed to have the event or was censored; D = 1*(T < C) where T is the time of the primary outcome and C is the censoring time
- so Surrogate marker measurement for control observations; this marker is measured at time = 0.5. For observations that experience the primary outcome or are censored before 0.5, this value is NA.
- x0 The observed event or censoring time for control observations; $X = \min(T, C)$ where T is the time of the primary outcome and C is the censoring time. This time is administratively censored at 0.55 (see details).
- delta0 The indicator identifying whether the control observation was observed to have the event or was censored; D = 1*(T < C) where T is the time of the primary outcome and C is the censoring time.

Details

Note that if the observation is censored or experienced the primary outcome before the landmark time of 0.50, the surrogate marker measurement is not observed and coded NA. In addition, Study B data is only observed up to the landmark time plus some epsilon, here epsilon=0.05 such that all observations are essentially administratively censored at time=0.55.

Examples

data(dataB)
names(dataB)

4 delta.estimate

delta.estimate	Calculates the treatment effect, the difference in survival at time t

Description

This function calculates the treatment effect in the survival setting i.e. the difference in survival at time t between the treatment group and the control group. The inverse probability of censoring weighted estimate of survival within each treatment group is used; there is an option to use the Kaplan-Meier estimate instead. This function is generally not expected to be used directly by the user, it is called by the recover.B function.

Usage

```
delta.estimate(xone, xzero, deltaone, deltazero, t, weight = NULL, KM = FALSE)
```

Arguments

xone	numeric vector, the observed event times in the treatment group, $X = \min(T,C)$ where T is the time of the primary outcome and C is the censoring time.
xzero	numeric vector, the observed event times in the control group, $X = \min(T,C)$ where T is the time of the primary outcome and C is the censoring time.
deltaone	numeric vector, the event indicators for the treatment group, $D = I(T < C)$ where T is the time of the primary outcome and C is the censoring time.
deltazero	numeric vector, the event indicators for the control group, $D = I(T < C)$ where T is the time of the primary outcome and C is the censoring time.
t	the time of interest.
weight	a $n_1 + n_0$ by x matrix of weights where $n_1 =$ sample size in the treatment group and $n_0 =$ sample size in the control group, default is null; generally not supplied by user, only used by other functions.
KM	true or false, indicating whether the Kaplan-Meier estimate of survival should be used instead of the inverse probability of censoring weighted estimate

Value

the difference in survival at time t (treatment group minus control group)

Author(s)

Layla Parast

design.study 5

Examples

```
data(dataA)
delta.estimate(xone = dataA$x1, xzero = dataA$x0, deltaone = dataA$delta1, deltazero =
dataA$delta0, t=1)

delta.estimate(xone = dataA$x1, xzero = dataA$x0, deltaone = dataA$delta1, deltazero =
dataA$delta0, t=0.5)
```

design.study

Power and sample size calculation for designing a future study

Description

Power and sample size calculation for designing a future study

Usage

```
design.study(Axzero, Adeltazero, Aszero, Axone = NULL, Adeltaone = NULL, Asone = NULL, delta.ea = NULL, psi = NULL, R.A.given = NULL, t, landmark, extrapolate = T, adjustment = F, n = NULL, power = NULL, pi.1 = 0.5, pi.0 = 0.5, cens.rate, transform = F)
```

Arguments

Axzero	observed event times in the control group in Study A
Adeltazero	event/censoring indicators in the control group in Study A
Aszero	surrogate marker values in the control group in Study A, NA for individuals not observable at the time the surrogate marker was measured
Axone	observed event times in the treatment group in Study A; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given)and psi or (3) data from treatment arm in Study A and hypothesized psi (if different from observed treatment effect at t in Study A))
Adeltaone	event/censoring indicators in the treatment group in Study A; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given)and psi or (3) data from treatment arm in Study A and hypothesized psi (if different from observed treatment effect at t in Study A))
Asone	surrogate marker values in the treatment group in Study A, NA for individuals not observable at the time the surrogate marker was measured; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given) and psi or (3) data from treatment arm in Study A and hypothesized psi (if different from observed treatment effect at t in Study A))
delta.ea	hypothesized value for the early treatment effect at time t0; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given) and psi or (3) data from treatment arm in Study A and

6 design.study

	hypothesized psi (if different from observed treatment effect at t in Study A)), if not given then it is assumed that this quantity equals the osberved early treatment effect at time t0 in Study A
psi	hypothesized value for the treatment effect at time t; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given) and psi or (3) data from treatment arm in Study A and hypothesized psi (if different from observed treatment effect at t in Study A)), if not given then it is assumed that this quantity equals the osberved treatment effect at time t in Study A
R.A.given	hypothesized value for the proportion of treatment effect on the primary outcome explained by surrogate information at t0 in Study A; optional (user must provide either (1) data from treatment arm in Study A or (2) hypothesized values for delta.ea (or R.A.given) and psi or (3) data from treatment arm in Study A and hypothesized psi (if different from observed treatment effect at t in Study A))
t	time of interest
landmark	landmark time of interest, t0
extrapolate	TRUE or FALSE; indicates whether local constant extrapolation should be used, default is TRUE
adjustment	TRUE or FALSE; indicates whether adjustment that is needed when survival past time t is high should be used, default is FALSE if survival past t0 is $<$ 0.90 in both arms arm of Study A, otherwise default is true if survival past t0 is $>$ 0.90 in either arm of Study A
n	total sample size for future study (Study B); optional (user needs to provide either n or power) $$
power	desired power for testing at time $t0$ for future study (Study B); optional (user needs to provide either n or power)
pi.1	proportion of total sample size in future study (Study B) that would be assigned to the treatment group, default is 0.5
pi.0	proportion of total sample size in future study (Study B) that would be assigned to the treatment group, default is 0.5
cens.rate	censoring in the future study (Study B) is assumed to follow an exponential distribution with censoring rate equal to this specificed value
transform	TRUE or FALSE; indicates whether a transformation should be used, default is FALSE.

Details

Assume information is available on a prior study, Study A, examining the effectiveness of a treatment up to some time of interest, t. The aim is to plan a future study, Study B, that would be conducted only up to time $t_0 < t$ and a test for a treatment effect would occur at t_0 . In both studies, we assume a surrogate marker is/will be measured at time t_0 for individuals still observable at t_0 . Let G be the binary treatment indicator with G=1 for treatment and G=0 for control and we assume throughout that subjects are randomly assigned to a treatment group at baseline. Let $T_K^{(1)}$ and $T_K^{(0)}$ denote the time of the primary outcome of interest, death for example, under the treatment and

design.study 7

under the control, respectively, in Study K. Let $S_K^{(1)}$ and $S_K^{(0)}$ denote the surrogate marker measured at time t_0 under the treatment and the control, respectively, in Study K.

The null and alternative hypotheses of interest are:

$$H_0: \Delta_B(t) \equiv P(T_B^{(1)} > t) - P(T_B^{(0)} > t) = 0$$

 $H_1: \Delta_B(t) = \psi > 0$

Here, we plan to test H_0 in Study B using the test statistic

$$Z_{EB}(t, t_0) = \sqrt{n_B} \frac{\hat{\Delta}_{EB}(t, t_0)}{\hat{\sigma}_{EB}(t, t_0)}$$

(see early.delta.test documentation). The estimated power at a type I error rate of 0.05 is thus

$$1 - \Phi \left\{ 1.96 - \frac{\sqrt{n_B} \hat{R}_{SA}(t, t_0) \psi}{\hat{\sigma}_{EB0}(t, t_0 \mid \hat{r}_A^{(0)}, W_B^C)} \right\}$$

where $\hat{R}_{SA}(t,t_0) = \hat{\Delta}_{EA}(t,t_0)/\hat{\Delta}_A(t)$, and

$$\hat{\Delta}_A(t) = n_{A1}^{-1} \sum_{i=1}^{n_{A1}} \frac{I(X_{Ai}^{(1)} > t)}{\hat{W}_{A1}^C(t)} - n_{A0}^{-1} \sum_{i=1}^{n_{A0}} \frac{I(X_{Ai}^{(0)} > t)}{\hat{W}_{A0}^C(t)},$$

and $\hat{\Delta}_{EA}(t,t_0)$ is parallel to $\hat{\Delta}_{EB}(t,t_0)$ except replacing $n_{A0}^{-1}\sum_{i=1}^{n_{A0}}\hat{r}_A^{(0)}(t|S_{Ai}^{(0)},t_0)\frac{I(X_{Ai}^{(0)}>t_0)}{\hat{W}_{A0}^C(t_0)}$ by $n_{A0}^{-1}\sum_{i=1}^{n_{A0}}\hat{W}_{A0}^C(t)^{-1}I(X_{Ai}^{(0)}>t)$, and $\hat{W}_{Ag}^C(\cdot)$ is the Kaplan-Meier estimator of the survival function for $C_A^{(g)}$ for g=0,1. In addition, $\hat{\sigma}_{EB0}(t,t_0|\hat{r}_A^{(0)},W_B^C)^2=$

$$\frac{1}{\pi_{B0}\pi_{B1}} \left[\frac{\hat{\mu}_{AB2}^{(0)}(t,t_0,\mid \hat{r}_A^{(0)})}{W_B^C(t_0)} - \hat{\mu}_{AB1}^{(0)}(t,t_0,\mid \hat{r}_A^{(0)})^2 \left\{ 1 + \int_0^{t_0} \frac{\lambda_B^C(u)du}{\hat{W}_{A0}^T(u)W_B^C(u)} \right\} \right]$$

assuming that the survival function of the censoring distribution is $W_B^C(t)$ in both arms, where $\pi_{Bg}=n_{Bg}/n_B$ and $\hat{W}_{A0}^T(\cdot)$ is the Kaplan-Meier estimator of the survival function of $T_A^{(0)}$ based on the observations from Study A, and

$$\hat{\mu}_{ABm}^{(0)}(t, t_0, | \hat{r}_A^{(0)}) = n_{A0}^{-1} \sum_{i=1}^{n_{A0}} \frac{\hat{r}_A^{(0)}(t | S_{Ai}^{(0)}, t_0)^m I(X_{Ai}^{(0)} > t_0)}{\hat{W}_{A0}^C(t_0)}$$

where $\hat{r}_A^{(0)}(t|s,t_0)$ is provided in the early.delta.test documentation.

This can be re-arranged to calculate the sample size needed in Study B to achieve a power of $100(1-\beta)\%$:

$$n_B = \left\{ \hat{\sigma}_{EB0}(t, t_0 \mid \hat{r}_A^{(0)}, W_B^C) \left(\frac{1.96 - \Phi^{-1}(\beta)}{\hat{R}_{SA}(t, t_0)\psi} \right) \right\}^2.$$

When the outcome rate is low (i.e., survival rate at t is high), an adjustment to the variance calculation is needed. This is automatically implemented if the survival rate at t in either arm is 0.90 or higher.

8 early.delta.test

Value

n Total sample size needed for Study B at the given power (if power is provided

by user).

power Estimated power for Study B at the given sample size (if sample size is provided

by user).

Author(s)

Layla Parast

References

Parast L, Cai T, Tian L (2019). Using a Surrogate Marker for Early Testing of a Treatment Effect. Biometrics, 75(4):1253-1263.

Examples

```
data(dataA)
design.study(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Axone = dataA$x1, Adeltaone = dataA$delta1, Asone = dataA$s1, t=1, landmark=0.5,
power = 0.80, cens.rate=0.5)

design.study(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Axone = dataA$x1, Adeltaone = dataA$delta1, Asone = dataA$s1, t=1, landmark=0.5,
n=2500, cens.rate=0.5)

design.study(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Axone = dataA$x1, Adeltaone = dataA$delta1, Asone = dataA$s1, t=1, landmark=0.5,
power = 0.80, cens.rate=0.5, psi = 0.05)
```

early.delta.test

Estimate and test the early treatment effect

Description

Estimates the early treatment effect estimate and provides two versions of the standard error; tests the null hypothesis that this treatment effect is equal to 0

Usage

```
early.delta.test(Axzero, Adeltazero, Aszero, Bxzero, Bxze
```

early.delta.test 9

Arguments

Axzero observed event times in the control group in Study A

Adeltazero event/censoring indicators in the control group in Study A

Aszero surrogate marker values in the control group in Study A, NA for individuals not

observable at the time the surrogate marker was measured

Bxzero observed event times in the control group in Study B

Bdeltazero event/censoring indicators in the control group in Study B

Bszero surrogate marker values in the control group in Study B, NA for individuals not

observable at the time the surrogate marker was measured

Bxone observed event times in the treatment group in Study B

Bdeltaone event/censoring indicators in the treatment group in Study B

Bsone surrogate marker values in the treatment group in Study B, NA for individuals

not observable at the time the surrogate marker was measured

t time of interest

landmark time of interest, t0

perturb TRUE or FALSE; indicates whether the standard error estimate obtained using

perturbation resampling should be calculated

extrapolate TRUE or FALSE; indicates whether local constant extrapolation should be used,

default is TRUE

transform TRUE or FALSE; indicates whether a transformation should be used, default is

FALSE.

Details

Assume there are two randomized studies of a treatment effect, a prior study (Study A) and a current study (Study B). Study A was completed up to some time t, while Study B was stopped at time $t_0 < t$. In both studies, a surrogate marker was measured at time t_0 for individuals still observable at t_0 . Let G be the binary treatment indicator with G=1 for treatment and G=0 for control and we assume throughout that subjects are randomly assigned to a treatment group at baseline. Let $T_K^{(1)}$ and $T_K^{(0)}$ denote the time of the primary outcome of interest, death for example, under the treatment and under the control, respectively, in Study K. Let $S_K^{(1)}$ and $S_K^{(0)}$ denote the surrogate marker measured at time t_0 under the treatment and the control, respectively, in Study K.

The treatment effect quantity of interest, $\Delta_K(t)$, is the difference in survival rates by time t under treatment versus control,

$$\Delta_K(t) = E\{I(T_K^{(1)} > t)\} - E\{I(T_K^{(0)} > t)\} = P(T_K^{(1)} > t) - P(T_K^{(0)} > t)$$

where $t > t_0$. Here, we estimate an early treatment effect quantity using surrogate marker information defined as,

$$\Delta_{EB}(t, t_0) = P(T_B^{(1)} > t_0) \int r(t|s, t_0) dF_B^{(1)}(s|t_0) - P(T_B^{(0)} > t_0) \int r(t|s, t_0) dF_B^{(0)}(s|t_0)$$

where
$$r(t|s,t_0) = P(T_A^{(0)} > t | T_A^{(0)} > t_0, S_A^{(0)} = s)$$
 and $F_B^{(g)}(s|t_0) = P(S_B^{(g)} \le s \mid T_B^{(g)} > t_0)$.

10 early.delta.test

To test the null hypothesis that $\Delta_B(t) = 0$, we test the null hypothesis $\Delta_{EB}(t,t_0) = 0$ using the test statistic

 $Z_{EB}(t,t_0) = \sqrt{n_B} \frac{\hat{\Delta}_{EB}(t,t_0)}{\hat{\sigma}_{EB}(t,t_0)}$

where $\hat{\Delta}_{EB}(t,t_0)$ is a consistent estimate of $\Delta_{EB}(t,t_0)$ and $\hat{\sigma}_{EB}(t,t_0)$ is the estimated standard error of $\sqrt{n_B}\{\hat{\Delta}_{EB}(t,t_0) - \Delta_{EB}(t,t_0)\}$. We reject the null hypothesis when $|Z_{EB}(t,t_0)| >$ $\Phi^{-1}(1-\alpha/2)$ where α is the Type 1 error rate.

To obtain $\hat{\Delta}_{EB}(t, t_0)$, we use

$$\hat{\Delta}_{EB}(t,t_0) = n_{B1}^{-1} \sum_{i=1}^{n_{B1}} \hat{r}_A^{(0)}(t|S_{Bi}^{(1)},t_0) \frac{I(X_{Bi}^{(1)} > t_0)}{\hat{W}_{B1}^{C}(t_0)} - n_{B0}^{-1} \sum_{i=1}^{n_{B0}} \hat{r}_A^{(0)}(t|S_{Bi}^{(0)},t_0) \frac{I(X_{Bi}^{(0)} > t_0)}{\hat{W}_{B0}^{C}(t_0)}$$

where $\hat{W}^{C}_{kg}(u)$ is the Kaplan-Meier estimator of $W^{C}_{kg}(u) = P(C^{(g)}_k > u)$ and $\hat{r}^{(0)}_A(t|s,t_0) = P(C^{(g)}_k > u)$ $\exp\{-\hat{\Lambda}_{A}^{(0)}(t \mid s, t_{0})\}\$, where

$$\hat{\Lambda}_{A}^{(0)}(t\mid t_{0},s) = \int_{t_{0}}^{t} \frac{\sum_{i=1}^{n_{A0}} I(X_{Ai}^{(0)} > t_{0}) K_{h}\{\gamma(S_{Ai}^{(0)}) - \gamma(s)\} dN_{Ai}^{(0)}(z)}{\sum_{i=1}^{n_{A0}} K_{h}\{\gamma(S_{Ai}^{(0)}) - \gamma(s)\} Y_{Ai}^{(0)}(z)}$$

is a consistent estimate of $\Lambda_A^{(0)}(t\mid t_0,s)=-\log[r_A^{(0)}(t\mid t_0,s)],\ Y_{Ai}^{(0)}(t)=I(X_{Ai}^{(0)}\geq t),$ $N_{Ai}^{(0)}(t)=I(X_{Ai}^{(0)}\leq t)\delta_{Ai}^{(0)},K(\cdot)$ is a smooth symmetric density function, $K_h(x)=K(x/h)/h$ and $\gamma(\cdot)$ is a given monotone transformation function. For the bandwidth h, we require the standard undersmoothing assumption of $h = O(n_q^{-\gamma})$ with $\gamma \in (1/4, 1/2)$ in order to eliminate the impact of the bias of the conditional survival function on the resulting estimator.

The quantity $\hat{\sigma}_{EB}(t,t_0)$ is obtained using either a closed form expression under the null or a perturbation resampling approach. If a confidence interval is desired, perturbation resampling is required.

Value

The estimate early treatment effect, $\hat{\Delta}_{EB}(t, t_0)$. delta.eb

se.closed The standard error estimate of the early treatment effect using the closed form

expression under the null.

Z.closed The test statistic using the closed form standard error expression.

p.value.closed The p-value using the closed form standard error expression.

conf.closed.norm

The confidence interval for the early treatment effect, using a normal approximation and using the closed form standard error expression.

The standard error estimate of the early treatment effect using perturbation rese.perturb sampling, if perturb = T.

The test statistic using the perturbed standard error estimate, if perturb = T. Z.perturb

p.value.perturb

The p-value using the perturbed standard error estimate, if perturb = T.

conf.perturb.norm

The confidence interval for the early treatment effect, using a normal approximation and using the perturbed standard error expression, if perturb = T.

delta.eb.CI The confidence interval for the early treatment effect, using the quantiles of the perturbed estimates, if perturb = T.

recover.B 11

Author(s)

Layla Parast

References

Parast L, Cai T, Tian L (2019). Using a Surrogate Marker for Early Testing of a Treatment Effect. Biometrics, 75(4):1253-1263.

Examples

```
data(dataA)
data(dataB)
early.delta.test(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Bxzero = dataB$x0, Bdeltazero = dataB$delta0, Bszero = dataB$s0, Bxone = dataB$x1,
Bdeltaone = dataB$delta1, Bsone = dataB$s1, t=1, landmark=0.5, perturb = FALSE,
extrapolate = TRUE)

early.delta.test(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Bxzero = dataB$x0, Bdeltazero = dataB$delta0, Bszero = dataB$s0, Bxone = dataB$x1,
Bdeltaone = dataB$delta1, Bsone = dataB$s1, t=0.75, landmark=0.5, perturb = FALSE,
extrapolate = TRUE)

early.delta.test(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0,
Bxzero = dataB$x0, Bdeltazero = dataB$delta0, Bszero = dataB$s0, Bxone = dataB$x1,
Bdeltaone = dataB$delta1, Bsone = dataB$s1, t=1, landmark=0.5, perturb = TRUE,
extrapolate = TRUE)
```

recover.B

Recover an estimate of the treatment effect at time t in Study B

Description

Recover an estimate of the treatment effect at time t in Study B

Usage

```
recover.B(Axzero, Adeltazero, Aszero, Axone, Adeltaone, Asone, Bxzero, Bdeltazero, Bszero, Bxone, Bdeltaone, Bsone, t, landmark, extrapolate = T, transform = F)
```

Arguments

Axzero observed event times in the control group in Study A

Adeltazero event/censoring indicators in the control group in Study A

Aszero surrogate marker values in the control group in Study A, NA for individuals not

observable at the time the surrogate marker was measured

12 recover.B

Axone observed event times in the treatment group in Study A

Adeltaone event/censoring indicators in the treatment group in Study A

Asone surrogate marker values in the treatment group in Study A, NA for individuals

not observable at the time the surrogate marker was measured

Bxzero observed event times in the control group in Study B
Bdeltazero event/censoring indicators in the control group in Study B

Bszero surrogate marker values in the control group in Study B, NA for individuals not

observable at the time the surrogate marker was measured

Bxone observed event times in the treatment group in Study B

Bdeltaone event/censoring indicators in the treatment group in Study B

Bsone surrogate marker values in the treatment group in Study B, NA for individuals

not observable at the time the surrogate marker was measured

t time of interest

landmark time of interest, t0

extrapolate TRUE or FALSE; indicates whether local constant extrapolation should be used,

default is TRUE

transform TRUE or FALSE; indicates whether a transformation should be used, default is

FALSE

Details

Assume there are two randomized studies of a treatment effect, a prior study (Study A) and a current study (Study B). Study A was completed up to some time t, while Study B was stopped at time $t_0 < t$. In both studies, a surrogate marker was measured at time t_0 for individuals still observable at t_0 . Let G be the binary treatment indicator with G=1 for treatment and G=0 for control and we assume throughout that subjects are randomly assigned to a treatment group at baseline. Let $T_K^{(1)}$ and $T_K^{(0)}$ denote the time of the primary outcome of interest, death for example, under the treatment and under the control, respectively, in Study K. Let $S_K^{(1)}$ and $S_K^{(0)}$ denote the surrogate marker measured at time t_0 under the treatment and the control, respectively, in Study K.

The treatment effect quantity of interest, $\Delta_K(t)$, is the difference in survival rates by time t under treatment versus control,

$$\Delta_K(t) = E\{I(T_K^{(1)} > t)\} - E\{I(T_K^{(0)} > t)\} = P(T_K^{(1)} > t) - P(T_K^{(0)} > t)$$

where $t > t_0$. Here, we recover an estimate of $\Delta_B(t)$ using Study B information (which stopped follow-up at time $t_0 < t$) and Study A information (which has follow-up information through time t). The estimate is obtained as

$$\hat{\Delta}_{EB}(t,t_0)/\hat{R}_{SA}(t,t_0)$$

where $\hat{\Delta}_{EB}(t,t_0)$ is the early treatment effect estimate in Study B, described in the early delta.test documention, and $\hat{R}_{SA}(t,t_0)$ is the proportion of treatment effect explained by the surrogate marker information at t_0 in Study A. This proportion is calculated as $\hat{R}_{SA}(t,t_0) = \hat{\Delta}_{EA}(t,t_0)/\hat{\Delta}_A(t)$ where

$$\hat{\Delta}_A(t) = n_{A1}^{-1} \sum_{i=1}^{n_{A1}} \frac{I(X_{Ai}^{(1)} > t)}{\hat{W}_{A1}^C(t)} - n_{A0}^{-1} \sum_{i=1}^{n_{A0}} \frac{I(X_{Ai}^{(0)} > t)}{\hat{W}_{A0}^C(t)},$$

recover.B 13

```
and \hat{\Delta}_{EA}(t,t_0) is parallel to \hat{\Delta}_{EB}(t,t_0) except replacing n_{A0}^{-1}\sum_{i=1}^{n_{A0}}\hat{r}_A^{(0)}(t|S_{Ai}^{(0)},t_0)\frac{I(X_{Ai}^{(0)}>t_0)}{\hat{W}_{A0}^C(t_0)} by n_{A0}^{-1}\sum_{i=1}^{n_{A0}}\hat{W}_{A0}^C(t)^{-1}I(X_{Ai}^{(0)}>t), and \hat{W}_{Ag}^C(\cdot) is the Kaplan-Meier estimator of the survival function for C_A^{(g)} for g=0,1.
```

Perturbation resampling is used to provide a standard error estimate for the estimate of $\Delta_B(t)$ and a confidence interval.

Value

```
recovered.deltaB
```

The recovered estimate of $\Delta_B(t)$.

sd.recovered.deltaB

The standard error estimate of the recovered estimate of $\Delta_B(t)$.

conf.quantile.recovered.deltaB

A confidence interval for the recovered estimate of $\Delta_B(t)$.

Author(s)

Layla Parast

References

Parast L, Cai T, Tian L (2019). Using a Surrogate Marker for Early Testing of a Treatment Effect. Biometrics, In press.

Parast L, Cai T and Tian L (2017). Evaluating Surrogate Marker Information using Censored Data. Statistics in Medicine, 36(11): 1767-1782.

Examples

```
data(dataA)
data(dataB)
recover.B(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0, Axone
= dataA$x1, Adeltaone = dataA$delta1, Asone = dataA$s1, Bxzero = dataB$x0, Bdeltazero
= dataB$delta0, Bszero = dataB$s0, Bxone = dataB$x1, Bdeltaone = dataB$delta1, Bsone
= dataB$s1, t=1, landmark=0.5, extrapolate = TRUE)

recover.B(Axzero = dataA$x0, Adeltazero = dataA$delta0, Aszero = dataA$s0, Axone
= dataA$x1, Adeltaone = dataA$delta1, Asone = dataA$s1, Bxzero = dataB$x0, Bdeltazero
= dataB$delta0, Bszero = dataB$s0, Bxone = dataB$x1, Bdeltaone = dataB$delta1, Bsone
= dataB$s1, t=0.75, landmark=0.5, extrapolate = TRUE)
```

Index

```
\ast datasets
    dataA, 2
    dataB, 3
* htest
    design.study, 5
    early.delta.test,8
* nonparametric
    delta.estimate, 4
    design.study, 5
    early.delta.test, 8
    recover.B, 11
* survival
    delta.estimate, 4
    design.study, 5
    early.delta.test,8
    recover.B, 11
* univar
    {\tt delta.estimate}, {\tt 4}
dataA, 2
dataB, 3
{\tt delta.estimate}, {\tt 4}
design.study, 5
early.delta.test,8
recover.B, 11
```